We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Groundbreaking New Approach for Celiac Disease

Groundbreaking New Approach for Celiac Disease content piece image
In an industrial collaboration project, TU Wien has developed a medication that can alleviate or even completely eliminate the symptoms of celiac disease. It should be available as early as 2021. Photo credit: Pixabay
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 2 minutes

Celiac disease is a fairly common disease, affecting one to two percent of the European population. It is expressed as a hypersensitivity to gluten, a protein found in cereals such as wheat, barley or rye.

Although efforts are already being made to treat celiac disease, the proposed drugs have an effect on the immune system. Possible side effects must therefore be examined very carefully. Although initial clinical studies are underway, they will not lead to a marketable product in the next few years.

For this reason, an entirely different approach has been pursued at TU Wien in collaboration with the industrial partner Sciotech Diagnostic Technologies GmbH. Instead of developing a drug that interferes with the immune system, TU Wien has created a simple medical product that directly attacks the gluten molecules to render them harmless. This makes the approval process much simpler, meaning that the product should be available in ordinary pharmacies as early as 2021.

Molecules like keys and locks

"Our bodies produce antibodies that fit intruding antigens precisely, like a key to a lock. This immune response makes these antigens harmless," explains Professor Oliver Spadiut, head of the Integrated Bioprocess Development Research Group at TU Wien. "If a new antibody fragment is found and produced that docks to and blocks the invading gluten molecule without triggering the immune system, the symptoms of celiac disease can be suppressed."

The aim of the research project was therefore to produce a complex of two such antibody fragments that envelop the gluten molecule at a molecular level, so that it can no longer have any further effects in the intestines.

To do this, certain bacteria have to be reprogrammed so that they produce exactly the desired antibody fragment. "The formation of such proteins in a bacterium is a highly complicated process," explains Oliver Spadiut. "It can easily happen that the proteins are not folded exactly as we want." Instead of the desired antibody fragments, so-called "inclusion bodies" are formed – small particles consisting of incorrectly folded proteins. A process therefore had to be developed to refold these inclusion bodies and to obtain the desired proteins from them.

Such processes, in which the folding of proteins is specifically altered, have not yet been studied in great detail and so they are not very efficient.

"You have to precisely understand the chemical processes involved and intervene in a complicated way," says Oliver Spadiut.

"It has therefore taken a while, but we have now developed a process that can be easily reproduced, can be scaled up to industrial application and delivers a very good yield of the desired product."
In pharmacies soon

The project was supported by the industrial partner SCIOTEC Diagnostic Technologies GmbH, who will now bring the new medical product to the market. "It will be a preparation that celiac patients can take together with gluten-containing foods to alleviate coeliac symptoms," explains Oliver Spadiut.

"It remains to be seen whether the symptoms will disappear completely or will only be alleviated. The precise effects will probably vary from person to person. In any case, we firmly expect the product to be available in ordinary pharmacies as early as 2021." 

This article has been republished from materials provided by the Vienna University of Technology. Note: material may have been edited for length and content. For further information, please contact the cited source.

Eggenreich, B., Scholz, E., Wurm, D. J., Forster, F., & Spadiut, O. (2018). The production of a recombinant tandem single chain fragment variable capable of binding prolamins triggering celiac disease. BMC Biotechnology, 18(1). doi:10.1186/s12896-018-0443-0